Literature DB >> 6607776

Interleukin 2 enhances natural killing of normal lymphocytes.

N Miyasaka, B Darnell, S Baron, N Talal.   

Abstract

Purified Interleukin 2 (IL-2), free of interferon (IFN), significantly enhanced NK activity of normal human peripheral blood mononuclear cells (PBMC). This enhancing activity was absorbed by IL-2 receptor-bearing cells but was not blocked by antibody to alpha-IFN. IFN in the culture supernatants was greatly increased after stimulation with poly(I:C) plus IL-2. There was less IFN produced by either modulator acting alone. Stimulation of PBMC with IL-2 and/or poly(I:C) increased the proportion of OKM1+ cells and anti-Leu-7+ cells. When cells expressing either surface antigen were specifically lysed to deplete NK, cytotoxic activity could be restored by overnight incubation in IL-2. This result suggests that IL-2 stimulates the development of NK cells from precursors that lack cell surface OKM1 or Leu-7. IL-2 acted directly on large granular lymphocytes and did not require the presence of adherent cells. These results suggest that IL-2 may act synergistically with other IFN inducers and may play an important role in the regulation of NK cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6607776     DOI: 10.1016/0008-8749(84)90086-8

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  17 in total

1.  Interleukin 2 enhances natural killing of varicella-zoster virus-infected targets.

Authors:  M Ito; S Bandyopadhyay; M Matsumoto-Kobayashi; S C Clark; D Miller; S E Starr
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

2.  Effects of interferons and interleukin 2 on natural killing of cytomegalovirus-infected fibroblasts.

Authors:  S Bandyopadhyay; D S Miller; M Matsumoto-Kobayashi; S C Clark; S E Starr
Journal:  Clin Exp Immunol       Date:  1987-02       Impact factor: 4.330

3.  The relationship between clinical stage, natural killer activity and related immunological parameters in adenocarcinoma of the prostate.

Authors:  N Lahat; B Alexander; D R Levin; B Moskovitz
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Deficiency of NK activity of HNK-1+ cells after transplantation of fetal thymus and liver or haploidentical soybean agglutinin-treated marrow cells in two severe combined immunodeficiency patients.

Authors:  Y I Gotoh; Y Yamaguchi; M Minegishi; T Konno; K Tada
Journal:  Clin Exp Immunol       Date:  1985-09       Impact factor: 4.330

5.  Association of reduced interleukin-2 production with genetic susceptibility to Pichinde virus in inbred strains of hamsters.

Authors:  K E Wright; K L Rosenthal; W E Rawls
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

6.  Partial restoration of impaired interleukin-2 production and Tac antigen (putative interleukin-2 receptor) expression in patients with acquired immune deficiency syndrome by isoprinosine treatment in vitro.

Authors:  K Y Tsang; H H Fudenberg; G M Galbraith; R P Donnelly; L R Bishop; W R Koopmann
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

7.  A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma.

Authors:  P B Chapman; J E Kolitz; T B Hakes; J L Gabrilove; K Welte; V J Merluzzi; A Engert; E C Bradley; M Konrad; R Mertelsmann
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

8.  The nature of the natural killer (NK) cell of human intestinal mucosa and mesenteric lymph node.

Authors:  P R Gibson; D P Jewell
Journal:  Clin Exp Immunol       Date:  1985-07       Impact factor: 4.330

9.  Independence of depressed lectin-dependent cell-mediated cytotoxicity from interleukin 2 production in patients with systemic lupus erythematosus.

Authors:  A Perl; R González-Cabello; K Onody; I Bodó; P Gergely
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

10.  Interleukin 2 defect in the peripheral blood and the lung in patients with Sjögren's syndrome.

Authors:  N Miyasaka; N Murota; K Yamaoka; K Sato; T Yamada; T Nishido; M Okuda
Journal:  Clin Exp Immunol       Date:  1986-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.